At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 97 enrolled
Drug / intervention
AM1476 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AM1476 - A Phase I, Double-blind, Placebo-controlled, Single- and Multiple-oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating AM1476 and Placebo for Safety and Tolerability. Completed, enrolled 97 participants across 1 site.
Detailed Summary
This is a First in Human (FIH), double-blind, randomised, placebo-controlled study designed to evaluate safety, tolerability and pharmacokinetics (PK) of single and multiple ascending oral doses of AM1476 in healthy subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSafety, Tolerability
CountriesUnited Kingdom
CollaboratorsCovance
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedDec 2020
Primary CompletionDec 2021
TodayJul 2026
First PostedDec 31, 2020
Enrollment StartDec 16, 2020
Primary CompletionDec 8, 2021
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 5.5 years ago
Interventions
AM1476drug
AM1476 Capsules
Placebodrug
Placebo Capsules